ECMI-1 project investigates how individual patient characteristics—such as molecular profiles, immune markers, and clinical subtypes—influence the effectiveness of mesenchymal stem cell (MSC) therapy in Amyotrophic Lateral Sclerosis (ALS). By integrating omics data with clinical and immunological insights, the study identifies key biomarkers that predict therapeutic outcomes. This research supports a precision medicine approach to MSC therapy in ALS, aiming to match the right treatment to the right patient and improve safety, efficacy, and clinical impact.

ECMI-2 project explores how partial cellular reprogramming can reverse age-related molecular changes without erasing cellular identity. By using defined reprogramming factors, researchers aim to restore youthful DNA methylation patterns and chromatin states in human cells and aged tissues. This innovative approach could lay the groundwork for safe, targeted rejuvenation therapies—opening new frontiers in regenerative medicine and healthy aging.

ECMI-3 introduces CardioThera 1.0, a personalized regenerative therapy for chronic heart failure and post-heart attack recovery. By integrating cutting-edge cell types—like cardiosphere-derived and mesenchymal precursor cells—with genomic profiling and real-time monitoring, CardioThera™ targets damaged heart tissue, reduces inflammation, and promotes healing where it’s needed most. This adaptive, precision-based approach offers a powerful new path toward restoring heart function and preventing long-term deterioration.

NEUROTHERA™ 1.0 is a next-generation personalized cell-based therapy targeting Hereditary Cerebellar Ataxias (HCA). At the core of the approach is P7NT1, a precision-engineered treatment combining genomic profiling, neuroprotection, and regenerative medicine. By activating the Nrf2 pathway and inhibiting NF-κB-driven inflammation, NEUROTHERA™ restores neural function and resilience. Early clinical results show promising safety and efficacy, positioning this therapy as a pioneering solution in regenerative neurotherapeutics.

OncoThera 1.0 pioneers personalized cancer vaccination (P7CV) by combining tumor molecular profiling with AI-assisted neoantigen selection. This approach customizes immune activation using targeted therapies—including NK cells, T cells, dendritic cells, and oncolytic viruses—tailored to each patient's tumor biology. By integrating machine learning and multi-modal immunotherapy, OncoThera™ delivers next-generation precision treatments that improve response, durability, and safety in cancer care.